Download PDF
CC BY-NC-ND 4.0 · Journal of Coloproctology 2021; 41(02): 188-192
DOI: 10.1055/s-0041-1725047
Review Article

Association between UGT1A1*28 Gene Polymorphism and Severe Neutropenia due to Colorectal Cancer Treatment with Irinotecan: Evidence Based on Meta-Analysis

Associação entre o polimorfismo do gene UGT1A1*28 e a neutropenia severa decorrente do tratamento do câncer colorretal com irinotecano: evidências baseadas em meta-análise
Tayná Aparecida de Oliveira Santos 
1   Biomedicine Course, Universidade Paulista (UNIP), Goiânia, GO, Brazil
,
Jacqueline Andréia Bernardes Leão-Cordeiro 
2   Faculdade de Enfermagem (FEN), Universidade Federal de Goiás (UFG), Goiânia, GO, Brazil
,
Daiane de Oliveira Cunha 
3   Programa de Pós-Graduação, Mestrado em Ciências Ambientais e Saúde (MCAS), Pontifícia Universidade Católica de Goiás (PUC Goiás), Goiânia, GO, Brazil
,
Cesar Augusto Sam Tiago Vilanova-Costa 
4   Tumoral Biology and Oncogenetics Laboratory, Hospital Araújo Jorge, Goiânia, GO, Brazil
,
Xisto Sena Passos 
1   Biomedicine Course, Universidade Paulista (UNIP), Goiânia, GO, Brazil
,
Antonio Márcio Teodoro Cordeiro Silva 
3   Programa de Pós-Graduação, Mestrado em Ciências Ambientais e Saúde (MCAS), Pontifícia Universidade Católica de Goiás (PUC Goiás), Goiânia, GO, Brazil
5   Medicine Course, Escola de Ciências Médicas, Farmacêuticas e Bimomédicas (EMFB), Pontifícia Universidade Católica de Goiás (PUC Goiás), Goiânia, GO, Brazil
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objective The present study aimed to evaluate the relationship between UGT1A1*28 gene polymorphism and the prevalence of neutropenia in patients with colorectal cancer treated with irinotecan.

Method Thirteen studies were included. These papers were selected from the Virtual Health Library, Scientific Electronic Library Online, International Health Sciences Literature and PubMed, and their data were collected and evaluated using the BioEstat 5.3 software (BioEstat, Belém, PA, Brazil).

Results Three genotypes were analyzed, namely 6/6 (wild type), 6/7, and 7/7. In total, 2,146 patients were included in the present study; of these, 55.6% (n = 1,193) had 6/6 genotype, 37.3% (n = 801) were heterozygous (6/7), and 7.1% (n = 152) had the 7/7 genotype. A total of 1,672 (77.9%) patients displayed mild neutropenia, whereas 474 (22.1%) had severe neutropenia. When contrasting the 6/7 and 7/7 genotypes with the 6/6 genotype using statistical tests for meta-analysis, patients with the 7 allele, either in homozygosis or heterozygosis, presented higher risk of developing severe neutropenia than patients with the 6/6 genotype (odds ratio = 1.559; 95% confidence interval = 1.163–2.090; p = 0.003).

Conclusion The analysis of the UGT1A1*28 gene polymorphism can aid the choice of treatment for patients with colorectal cancer in personalized medicine, increasing the chances of therapeutic success.

Resumo

Objetivo Avaliar a relação do polimorfismo do gene UGT1A1*28 com a prevalência de neutropenia em pacientes com câncer colorretal submetidos a tratamento com o irinotecano.

Método Foram incluídos 13 estudos sobre o tema proposto, selecionados nas bases de dados da Biblioteca Virtual de Saúde, Scientific Electronic Library Online, International Health Sciences Literature e PubMed. Os dados foram coletados dos artigos científicos selecionados e avaliados com o auxílio do software BioEstat 5.3 (BioEstat, Belém, PA, Brasil).

Resultados Os genótipos analisados foram 6/6 (tipo selvagem), 6/7 e 7/7. Foram incluídos 2.146 pacientes. Destes, 55,6% (n = 1.193) apresentaram genótipo 6/6, 37,3% (n = 801) eram heterozigotos (6/7) e 7,1% (n = 152) tinham o genótipo 7/7. Um total de 1.672 (77,9%) pacientes apresentou neutropenia leve e 474 (22,1%) neutropenia severa. Ao contrastar os genótipos 6/7 e 7/7 com o 6/6, percebeu-se, com a execução dos testes estatísticos de meta-análise, que os pacientes com o alelo 7, em homozigose ou heterozigose, tinham maior risco de desenvolver neutropenia severa que pacientes com o genótipo 6/6 (razão de chances = 1,559; intervalo de confiança de 95% = 1,163–2,090; p = 0,003).

Conclusão A análise do polimorfismo do gene UGT1A1*28 pode auxiliar na escolha do tratamento do paciente com câncer colorretal, no contexto da medicina personalizada, ampliando, assim, as chances de sucesso terapêutico.

Keywords

neutropenia - colorectal cancer - polymorphisms

Palavras-chave

neutropenia - câncer colorretal - polimorfismos


Publication History

Received: 21 May 2020

Accepted: 11 August 2020

Article published online:
30 June 2021

© 2021. Sociedade Brasileira de Coloproctologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 INCA. Incidência de Câncer no Brasil. 2018
    PubMedGoogle Scholar
  • 2 Junqueira MZ, Chammas R. Cancer chemotherapy failure: a synthetic view. Rev Med (São Paulo) 2018; 97 (02) 1-3
    CrossrefGoogle Scholar
  • 3 Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J 2014; 14 (02) 120-129
    CrossrefPubMedGoogle Scholar
  • 4 Dean L. Irinotecan Therapy and UGT1A1 Genotype Drug: Irinotecan. 2009. ;(Md) 1-8
    Google Scholar
  • 5 Brockmöller J, Tzvetkov MV. Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol 2008; 64 (02) 133-157
    CrossrefPubMedGoogle Scholar
  • 6 Shulman K, Cohen I, Barnett-Griness O. et al. Colorectal Cancer Patients. 2012; 117 (14) 3156-3162
  • 7 Nakanishi M. Precision medicine. Rev Bras Otorrinolaringol (Engl Ed) 2018; 84 (03) 263-264
    Google Scholar
  • 8 dos Santos EJF, Cunha M. Interpretação crítica dos resultados estatísticos de uma meta-análise: estratégias metodológicas. Millenium. 2013; 44: 85-98
    Google Scholar
  • 9 McLeod HL, Sargent DJ, Marsh S. et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28 (20) 3227-3233
    CrossrefPubMedGoogle Scholar
  • 10 Glimelius B, Garmo H, Berglund A. et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 2011; 11 (01) 61-71
    CrossrefPubMedGoogle Scholar
  • 11 Braun MS, Richman SD, Thompson L. et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 2009; 27 (33) 5519-5528
    CrossrefPubMedGoogle Scholar
  • 12 Toffoli G, Cecchin E, Corona G. et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24 (19) 3061-3068
    CrossrefPubMedGoogle Scholar
  • 13 Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJA, Guchelaar HJ. Dutch Colorectal Cancer Group study. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 2008; 99 (02) 275-282
    CrossrefPubMedGoogle Scholar
  • 14 Ruzzo A, Graziano F, Loupakis F. et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 2008; 8 (04) 278-288
    CrossrefPubMedGoogle Scholar
  • 15 Liu D, Li J, Gao J, Li Y, Yang R, Shen L. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC Cancer 2017; 17 (01) 437
    CrossrefPubMedGoogle Scholar
  • 16 Rouits E, Boisdron-Celle M, Dumont A, Guérin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10 (15) 5151-5159
    CrossrefPubMedGoogle Scholar
  • 17 Carlini LE, Meropol NJ, Bever J. et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11 (03) 1226-1236
    CrossrefPubMedGoogle Scholar
  • 18 Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91 (04) 678-682
    CrossrefPubMedGoogle Scholar
  • 19 Stewart CF, Panetta JC, O'Shaughnessy MA. et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007; 25 (18) 2594-2600
    CrossrefPubMedGoogle Scholar
  • 20 Bai Y, Wu HW, Ma X, Liu Y, Zhang YH. Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy. OncoTargets Ther 2017; 10: 3071-3081
    CrossrefPubMedGoogle Scholar
  • 21 Côté JF, Kirzin S, Kramar A. et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13 (11) 3269-3275
    CrossrefPubMedGoogle Scholar